SHCR vs. DCGO, MYPS, TALK, LTCH, WGS, INNV, PNTG, ADCT, TMCI, and URGN
Should you be buying Sharecare stock or one of its competitors? The main competitors of Sharecare include DocGo (DCGO), PLAYSTUDIOS (MYPS), Talkspace (TALK), Latch (LTCH), GeneDx (WGS), InnovAge (INNV), The Pennant Group (PNTG), ADC Therapeutics (ADCT), Treace Medical Concepts (TMCI), and UroGen Pharma (URGN).
Sharecare (NASDAQ:SHCR) and DocGo (NASDAQ:DCGO) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, community ranking, institutional ownership, analyst recommendations, risk, profitability and earnings.
DocGo has higher revenue and earnings than Sharecare. Sharecare is trading at a lower price-to-earnings ratio than DocGo, indicating that it is currently the more affordable of the two stocks.
In the previous week, Sharecare had 10 more articles in the media than DocGo. MarketBeat recorded 12 mentions for Sharecare and 2 mentions for DocGo. DocGo's average media sentiment score of 1.29 beat Sharecare's score of 0.34 indicating that DocGo is being referred to more favorably in the news media.
DocGo received 34 more outperform votes than Sharecare when rated by MarketBeat users. Likewise, 73.21% of users gave DocGo an outperform vote while only 38.89% of users gave Sharecare an outperform vote.
35.1% of Sharecare shares are owned by institutional investors. Comparatively, 56.4% of DocGo shares are owned by institutional investors. 29.3% of Sharecare shares are owned by insiders. Comparatively, 2.7% of DocGo shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
DocGo has a net margin of 2.98% compared to Sharecare's net margin of -30.71%. DocGo's return on equity of 6.20% beat Sharecare's return on equity.
Sharecare currently has a consensus price target of $1.50, suggesting a potential upside of 95.80%. DocGo has a consensus price target of $7.75, suggesting a potential upside of 147.60%. Given DocGo's stronger consensus rating and higher possible upside, analysts clearly believe DocGo is more favorable than Sharecare.
Sharecare has a beta of 0.26, meaning that its stock price is 74% less volatile than the S&P 500. Comparatively, DocGo has a beta of 0.96, meaning that its stock price is 4% less volatile than the S&P 500.
Summary
DocGo beats Sharecare on 15 of the 18 factors compared between the two stocks.
Get Sharecare News Delivered to You Automatically
Sign up to receive the latest news and ratings for SHCR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SHCR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Sharecare Competitors List
Related Companies and Tools
